Filtered By:
Specialty: Cardiology
Condition: Cardiogenic Shock
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 235 results found since Jan 2013.
Patient characteristics and outcomes of acute myocardial infarction presenting without ischemic pain: Insights from the Atherosclerosis Risk in Communities Study
CONCLUSIONS: Future research should focus on differences in treatment delay across ischemic pain presentations rather than sex differences in acute coronary syndrome presentation.PMID:36713888 | PMC:PMC9879363 | DOI:10.1016/j.ahjo.2022.100239
Source: Atherosclerosis - January 30, 2023 Category: Cardiology Authors: Bailey M DeBarmore Jessica K Z ègre-Hemsey Anna M Kucharska-Newton Erin D Michos Wayne D Rosamond Source Type: research
Short-Term Outcomes of Impella Support in Japanese Patients With Cardiogenic Shock Due to Acute Myocardial Infarction - Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD)
CONCLUSIONS: AMICS treatment with Impella showed favorable 30-day survival and safety profiles. The survival rate of patients treated with Impella alone was particularly high. Further studies are needed to improve outcomes of patients with ECPELLA support.PMID:36682787 | DOI:10.1253/circj.CJ-22-0476
Source: Circulation Journal - January 22, 2023 Category: Cardiology Authors: Yuki Ikeda Junya Ako Koichi Toda Atsushi Hirayama Koichiro Kinugawa Yoshio Kobayashi Minoru Ono Takashi Nishimura Naoki Sato Takahiro Shindo Morimasa Takayama Satoshi Yasukochi Akira Shiose Yoshiki Sawa J-PVAD Investigators Source Type: research
Causes of Death in Elderly Patients With Non-Valvular Atrial Fibrillation - Results From the ANAFIE Registry
CONCLUSIONS: This subanalysis described the mortality according to causes of death of Japanese elderly NVAF patients in the DOAC era. Our results imply that a more holistic approach to comorbid conditions and stroke prevention are required in these patients.PMID:36653127 | DOI:10.1253/circj.CJ-22-0614
Source: Circulation Journal - January 18, 2023 Category: Cardiology Authors: Takeshi Yamashita Masaharu Akao Hirotsugu Atarashi Takanori Ikeda Yukihiro Koretsune Ken Okumura Wataru Shimizu Shinya Suzuki Hiroyuki Tsutsui Kazunori Toyoda Atsushi Hirayama Masahiro Yasaka Takenori Yamaguchi Satoshi Teramukai Tetsuya Kimura Yoshiyuki M Source Type: research
Clonal hematopoiesis and cardiovascular disease: deciphering interconnections
AbstractCardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes areTET2,DNMT3A,ASXL1 andJAK2. By the age of 70, at least 20 –50% of all individuals carry a CH clone, conveying a striking clinical impact by increasing all-cause mortality by 40%. This is due predominantly to a nearly two-fold increase of cardiovascular risk, but also to ...
Source: Basic Research in Cardiology - November 10, 2022 Category: Cardiology Source Type: research
Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial
Conclusions: Immediate implementation of VA-ECMO in patients with rapidly deteriorating or severe cardiogenic shock did not improve clinical outcomes compared with an early conservative strategy that permitted downstream use of VA-ECMO in case of worsening hemodynamic status. Clinical Trial Registration: URL: https://www.clinicaltrials.gov; Unique identifier NCT02301819.PMID:36335478 | DOI:10.1161/CIRCULATIONAHA.122.062949
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Petr Ostadal Richard Rokyta Jiri Karasek Andreas Kruger Dagmar Vondrakova Marek Janotka Jan Naar Jana Smalcova Marketa Hubatova Milan Hromadka Stefan Volovar Miroslava Seyfrydova Jiri Jarkovsky Michal Svoboda Ales Linhart Jan Belohlavek ECMO-CS Investigat Source Type: research
Should targeted temperature management be used in cardiogenic shock patients? Systematic review and meta-analysis
CONCLUSIONS: The present analysis shows no significant benefit of TTM in patients with CS. Moreover, no statistically significant increase of the incidence of adverse effects was found. However, further randomized studies with higher sample size and greater validity are needed to determine if TTM is worth implementing in CS patients.PMID:36200546 | DOI:10.5603/CJ.a2022.0093
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Adam Nieborek Jerzy R Ladny Milosz J Jaguszewski Andrea Denegri Aleksandra Sikora Szymon Pucylo Aleksandra Gasecka Michal Pruc Ivan Savytsky Lukasz Szarpak Source Type: research
